Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

DAIICHI SANKYO COMPANY, LIMITED

(4568)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Communiqués de presse de la société DAIICHI SANKYO COMPANY, LIMITED
10/11DAIICHI SANKYO : Corporate Governance Report
PU
10/05DAIICHI SANKYO : Astrazeneca - Enhertu granted Breakthrough Therapy Designation in US for ..
AQ
09/20DAIICHI SANKYO : Enhertu reduced the risk of disease progression or death by 72% vs. trast..
AQ
09/20DAIICHI SANKYO : Enhertu demonstrated robust and durable tumour response of 54.9% in patie..
AQ
09/20DAIICHI SANKYO : Enhertu demonstrated clinically meaningful and durable response in patien..
AQ
09/18DAIICHI SANKYO : ENHERTU® Reduced the Risk of Disease Progression or Death by 72% Versus T..
BU
08/19Defence therapeutics selects the best 8 accumtm variants to optimize its adc therapeuti..
AQ
08/10LOGICBIO THERAPEUTICS : Reports Second Quarter 2021 Financial Results and Highlights Recen..
AQ
08/10DAIICHI SANKYO : Enhertu significantly improved progression-free survival in DESTINY-Breas..
AQ
08/09DAIICHI SANKYO : ENHERTU® Significantly Improved Progression-Free Survival in DESTINY-Brea..
BU
07/30DAIICHI SANKYO : Consolidated Financial Results for the First Three Months of the Year End..
PU
07/30DAIICHI SANKYO : Top Management Presentation
PU
07/30DAIICHI SANKYO : Reference Data
PU
06/22DAIICHI SANKYO : Corporate Governance Report
PU
05/20CHICAGO LEADING THE WAY : New Educational Collaboration Seeks to Create a Clinical Action ..
AQ
05/13DAIICHI SANKYO : Announces the Introduction of a Trust-type Share-based Compensation Syste..
PU
05/13DAIICHI SANKYO : Announces Changes to Representative Directors, Directors and Audit & Supe..
PU
03/12DAIICHI SANKYO : Japanese drugmaker starts AstraZeneca vaccine production in Japan
AQ
01/18DAIICHI SANKYO : Enhertu approved in the US for the treatment of patients with previously ..
AQ
01/12DAIICHI SANKYO : AstraZeneca to showcase transformative data across diverse pipeline at Wo..
AQ
2020ESPERION THERAPEUTICS : Daiichi Sankyo - First-in-class cholesterol-lowering treatment NIL..
AQ
2020DAIICHI SANKYO : AstraZeneca - Trastuzumab deruxtecan recommended for approval in the EU b..
AQ
2020DAIICHI SANKYO : AstraZeneca - Enhertu continues to demonstrate durable responses with new..
AQ
2020DAIICHI SANKYO : Creates New Business Unit to Unify Major Oncology Markets into One Stream..
AQ
2020DAIICHI SANKYO : Successfully Defends Itself Against An Early Market Entry Of Generic Comp..
AQ
2020BioInvent Interim Report January 1 - September 30, 2020
AQ
2020DAIICHI SANKYO : RedHill Biopharma Adds Israel Rights to Movantik from AstraZeneca
AQ
2020DAIICHI SANKYO : Announces Establishment of DAIICHI SANKYO VIETNAM COMPANY LIMITED
AQ
2020DAIICHI SANKYO : Submits Supplemental Application in Japan for Approval of Partial Changes..
AQ
2020DAIICHI SANKYO : AnHeart Licenses Two Clinical Stage Oncology Candidates from Daiichi Sank..
AQ
2020DAIICHI SANKYO : Announces Results of Phase 3 Clinical Trial for Anticoagulant Edoxaban
AQ
2020DAIICHI SANKYO : Selected for AMED's 'Development of a Vaccine for COVID-19 Vaccines
AQ
2020DAIICHI SANKYO : Announces Clinical Trial Collaboration with AstraZeneca to Evaluate Patri..
AQ
2020DAIICHI SANKYO : Selected as Provider for Japanese Government's 'Emergent Initiative to Bu..
AQ
2020DAIICHI SANKYO : RedHill Biopharma Announces New Agreement with Daiichi Sankyo for Movanti..
AQ
2020DAIICHI SANKYO : and AstraZeneca Enter New Global Development and Commercialization Collab..
AQ
2020DAIICHI SANKYO : and AstraZeneca Enter New Global Development and Commercialization Collab..
BU
2020DAIICHI SANKYO : Announces Phase 3 Study Results for Prasugrel Antiplatelet Agent in Throm..
AQ
2020DAIICHI SANKYO : EMA Validates and Grants Accelerated Assessment for Trastuzumab Deruxteca..
AQ
2020DAIICHI SANKYO : Announces Participation in AMR Action Fund
AQ
2020DAIICHI SANKYO : EMA Validates and Grants Accelerated Assessment for Trastuzumab Deruxteca..
AQ
2020DAIICHI SANKYO : Announces Start of Discussions with AstraZeneca Regarding Supply in Japan..
AQ
2020DAIICHI SANKYO : Personal Jurisdiction Win In Pennsylvania
AQ
2020DAIICHI SANKYO : Announces Decision to Develop Vaccine in Japan for Novel Corona Virus Inf..
AQ
2020NICHI IKO PHARMACEUTICAL : The University of Tokyo, RIKEN, Nichi-Iko and Daiichi Sankyo Re..
AQ
2020DAIICHI SANKYO : Announces Clinical Research Collaboration to Evaluate DS-1062 in Combinat..
AQ
2020DAIICHI SANKYO : AstraZeneca - Enhertu significantly improved tumour response rate and ove..
AQ
2020DAIICHI SANKYO : AstraZeneca and Daiichi Sankyo Company, Limited - Enhertu achieved a tumo..
AQ
2020DAIICHI SANKYO : AstraZeneca - Enhertu demonstrated meaningful clinical activity in patien..
AQ
2020DAIICHI SANKYO : Launches ENHERTU in Japan for Patients with HER2 Positive Unresectable or..
AQ
2020DAIICHI SANKYO : ENHERTU Granted Orphan Drug Designation in the U.S. for Gastric Cancer
AQ
2020DAIICHI SANKYO : Initiates Clinical Trial with 5th DXd ADC, DS-6157, in Collaboration with..
AQ
2020DAIICHI SANKYO : ENHERTU Granted Orphan Drug Designation in the U.S. for Gastric Cancer
AQ
2020DAIICHI SANKYO : ENHERTU Granted Breakthrough Therapy Designation in the U.S. for HER2 Mut..
AQ
2020DAIICHI SANKYO : AstraZeneca - ENHERTU granted Breakthrough Therapy Designation in the US ..
AQ
2020DAIICHI SANKYO : Enhertu granted Breakthrough Therapy Designation in the US for HER2-mutan..
AQ
2020DAIICHI SANKYO : ENHERTU Granted Breakthrough Therapy Designation in the U.S. for HER2 Pos..
AQ
2020DAIICHI SANKYO : Submits Supplemental New Drug Application for Trastuzumab Deruxtecan in J..
BU
2020DAIICHI SANKYO : Announces Removal of Contaminated Soil Storage Facility from Site of Form..
AQ
2020DAIICHI SANKYO : Announces Share Split, Partial Amendment to the Articles of Incorporation..
AQ
2020DAIICHI SANKYO : Contributes to Relief Efforts for Countermeasures against COVID-19
AQ
2020DAIICHI SANKYO : Mitsubishi UFJ Capital and Nagoya Institute of Technology Announce Open I..
AQ
2020DAIICHI SANKYO : and Kitasato Pharmaceutical Industry to End Sales Cooperation for Influen..
AQ
2020DAIICHI SANKYO : ENHERTU Approved in Japan for Treatment of Patients with HER2 Positive Un..
AQ
2020Zymeworks Reports 2019 Year-End Financial Results
AQ
2020DAIICHI SANKYO : UCB Japan Co., Ltd - Anti-epilepsy Drug VIMPAT, Submission for Supplement..
AQ
2020RedHill Biopharma Acquires Rights to Movantik from AstraZeneca
AQ
2020DAIICHI SANKYO : Appoints New Corporate Officers
AQ
2020DAIICHI SANKYO : Phase 2 DESTINY-Gastric01 Trial of DS-8201 Versus Chemotherapy Met Primar..
BU
2020DAIICHI SANKYO : ENHERTU Now Available in U.S. for HER2 Positive Unresectable or Metastati..
AQ
2019DAIICHI SANKYO : AstraZeneca - Enhertu approved in the US for HER2-positive unresectable o..
AQ
2019DAIICHI SANKYO : ENHERTU Approved in the U.S. for HER2 Positive Unresectable or Metastatic..
AQ
2019DAIICHI SANKYO : Enhertu (trastuzumab deruxtecan) approved in the US for HER2-positive unr..
AQ
2019DAIICHI SANKYO : Launches Antitumor Agent Bevacizumab Biosimilar for Intravenous Drip Infu..
AQ
2019ASTRAZENECA : Trastuzumab deruxtecan achieved a tumour response rate of 60.9% in pivotal P..
AQ
1  2  3  4  5  6Next
Upcoming event on DAIICHI SANKYO COMPANY, LIMITED